Pharmacogenetics in Primary Care: The Promise of Personalized Medicine and the Reality of Racial Profiling
- 711 Downloads
Many anticipate that expanding knowledge of genetic variations associated with disease risk and medication response will revolutionize clinical medicine, making possible genetically based Personalized Medicine where health care can be tailored to individuals, based on their genome scans. Pharmacogenetics has received especially strong interest, with many pharmaceutical developers avidly working to identify genetic variations associated with individual differences in drug response. While clinical applications of emerging genetic knowledge are becoming increasingly available, genetic tests for drug selection are not as yet widely accessible, and many primary care clinicians are unprepared to interpret genetic information. We conducted interviews with 58 primary care clinicians, exploring how they integrate emerging pharmacogenetic concepts into their practices. We found that in their current practices, pharmacogenetic innovations have not led to individually tailored treatment, but instead have encouraged use of essentialized racial/ethnic identity as a proxy for genetic heritage. Current manifestations of Personalized Medicine appear to be reinforcing entrenched notions of inherent biological differences between racial groups, and promoting the belief that racial profiling in health care is supported by cutting-edge scientific authority. Our findings raise concern for how pharmacogenetic innovations will actually affect diverse populations, and how unbiased treatment can be assured.
KeywordsPharmacogenetics Personalized medicine Race and ethnicity Racial profiling
- AMA (American Medical Association) 2011 Pharmacogenomics: Increasing the Safety and Effectiveness of Drug Therapy. http://www.ama-assn.org/resources/doc/genetics/pgx-brochure-2011.pdf.
- DHHS (Department of Health and Human Services) 2006 Coverage and Reimbursement of Genetic Tests and Services. Report of the Secretary’s Advisory Committee on Genetics, Health and Society. http://oba.od.nih.gov/oba/sacghs/reports/CR_report.pdf.
- FDA, (Food and Drug Administration) 2010 Drug Safety Newsletter: EQUETRO® (Carbamazepine) Extended-Release Capsules Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021710s008lbl.pdf.
- Fullwiley, Duana 2011 The Enculturated Gene: Sickle Cell Health Politics and Biological Difference in West Africa. Princeton: Princeton University Press.Google Scholar
- Gaines, Atwood D 1998 Culture and Values at the Intersection of Science and Suffering: Encountering Ethics, Genetics and Alzheimer Disease. In Encountering Ethics, Genetics and Alzheimer Disease. In Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. S. G. Post, and P. J. Whitehouse, eds., pp. 256–274. Baltimore: Johns Hopkins University Press.Google Scholar
- Gaines, Atwood D. (2005). Race: Local Biology and Culture in Mind. In C. Casey & R. Edgerton (Eds.), Companion to Psychological Anthropology: Modernity and Psychocultural Change (pp. 255-278). Oxford: Blackwell.Google Scholar
- Hunt, Linda M., Truesdell, Nicole, & Kreiner, Meta J In Press Race, Genes and Culture in Primary Care: Racial Profiling in the Management of Chronic Illness. Medical Anthropology Quarterly.Google Scholar
- Jones, D. S. 2011 How Personalized Medicine Became Genetic, and Racial: Werner Kalow and the Formations of Pharmacogenetics. http://www.ncbi.nlm.nih.gov/pubmed/21908852.
- Kahn, Jonathan 2004 How a Drug Becomes “Ethnic”: Law, Commerce, and the Production of Racial Categories in Medicine. Yale Journal of Health Policy, Law, and Ethics 4(1):1–46.Google Scholar
- Kahn, Jonathan 2009 Beyond Bidil: The Expanding Embrace Of Race In Biomedical Research And Product Development. Saint Louis University Journal Of Health Law & Policy 3(61):61-92.Google Scholar
- UpToDate 2012 Evidence-Based Clinical Decision Support Resource. http://www.uptodate.com/index.